Patients experiencing emotional distress and with stage IV solid tumour cancer will be included in the study. Credit: Africa Studio/Shutterstock.com.

MindBio Therapeutics has started enrolling patients in its Phase II trial evaluating microdoses of lysergic acid diethylamide (LSD) combined with meaning-centred psychotherapy in advanced-stage cancer patients experiencing emotional distress.

The initiation of the study is based on the ethics approval received last month.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The six-week placebo-controlled, double-blind, randomised study of 40 participants is claimed to be the world’s first LSD take-home trial.

Patients experiencing emotional distress and with stage IV solid tumour cancer will be included in the study.

Advanced-stage cancer patients often develop constant, clinically important, symptoms of psychological distress.

Such patients also experience a high prevalence of depression, anxiety and minimised quality of life and 40% of those meet the mood disorder criteria.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These disorders can highly impact a patient’s end-of-life experience and can trigger feelings of loss of meaning, hope, or a desire for hastened death, considered as one of the most challenging problems in palliative medicine.

Anxiety and depression in these patients have also been associated with increased suicidality, prolonged hospitalisation, decreased quality of life and treatment adherence.

Depression is considered to be an independent factor in the risk of early death in cancer patients.

MindBio Therapeutics co-founder and CEO Justin Hanka said: “This research proposes to completely change the way we treat the mental health of cancer patients.

“End-of-life distress is devastating to patients and their families and psychedelics are known to completely transform an individual’s psychological state near the end of life.

“We already know that our LSD-microdosing treatments are well tolerated and effective at elevating mood and improving sleep, our thesis is that small doses of psychedelics will be well tolerated and highly beneficial to this vulnerable patient group.”